Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-10-04
2005-10-04
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S183000, C514S494000, C514S561000, C514S562000, C514S578000, C514S725000, C424S641000, C424S643000
Reexamination Certificate
active
06951890
ABSTRACT:
Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.
REFERENCES:
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4866090 (1989-09-01), Hoffman et al.
patent: 4952568 (1990-08-01), Sawai et al.
patent: 5077313 (1991-12-01), Lubec
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5387109 (1995-02-01), Ishikawa et al.
patent: 5852009 (1998-12-01), Cerami et al.
patent: 6147070 (2000-11-01), Facchini
patent: 6348465 (2002-02-01), Baker
patent: 6610693 (2003-08-01), Baker
patent: 2002/0034775 (2002-03-01), Baker
patent: 2003/0045506 (2003-03-01), Baker
patent: 30918/89 (1989-09-01), None
patent: 0 426 066 (1991-05-01), None
patent: 7118148 (1995-05-01), None
patent: 2000204037 (2000-07-01), None
patent: WO 85/04169 (1985-09-01), None
patent: WO 95/17900 (1995-07-01), None
patent: WO 96/12483 (1996-05-01), None
patent: WO 00/18392 (2000-04-01), None
patent: WO/00/18392 (2000-04-01), None
patent: WO 00/18891 (2000-04-01), None
patent: PCT/NZ03/00042 (2003-03-01), None
patent: WO/2003/075910 (2003-09-01), None
patent: WO/2003/077901 (2003-09-01), None
patent: WO/2004/017957 (2004-03-01), None
Encyclopedia of Toxicology, vol. 1, Philip Wexler, ed. published 1998 by Academic Press (San Diego) pp. 376-378.
Pasterkamp & Falk, “Atherosclerotic Plaque Rupture: an Overview,” J. Clin. Basic Cardiol. 3:81-86 (2000).
Allen et al., “Tetramine Cupruretic Agents: A Comparison in Dogs”,Am J Vet Res, vol. 48, No. 1, Jan. 1987.
American Diabetes Association, “Economic Consequences of Diabetes Mellitus in the U.S. in 1997”,Diabetes Care, vol. 21, No. 2., Feb. 1998.
Appelbaum et al., “The Protective Role of Neocuproine Against Cardiac Damage in Isolated Perfused Rat Hearts”,Free Radical Biology & Medicine, vol. 8, pp. 133-143, 1990; Pergamon Press USA.
Haynes, “Role of Oxidative Stress in Development of Complications in Diabetes”,Diabetes, vol. 40, Apr. 1991.
Baynes et al., “Role of Oxidative Stress in Diabetic Complications A New Perspective on an Old Paradigm”,Diabetes, vol. 48, Jan. 1999.
Berenshtein et al., “Roles of Ferritin and Iron in Ischemic Preconditioning of the Heart”,Molecular and Cellular Biochemistry, 234/235: 283-292, 2002; Kluwer Academic Publishers, Netherlands.
Borthwick et al., “A Comparison of Cupruretic Responses to Various Tetramines and D-Penicillamine”,J Lab Clin Med95:575, 1980.
Bryszewska et al., “Oxidative Processes in Red Blood Cells from Normal and Diabetic Individuals”,Biochemistry and Molecular Biology International, vol. 37, No. 2, 345-354, Oct. 1995.
Cameron et al., “Ciliary Neuronotrophic Factor Improves Nerve Conduction and Regeneration in Experimental Diabetes”,Diabetologia38, (Suppl. 1):A233 (Abstract), no date available.
Cameron et al., “Neurovascular Dysfunction in Diabetic Rats,”J. Clin. Invest., 1995 96:1159-1163.
Chaturvedi, et al., “Effect of Lisinopril on Progression of Retinopathy in Normotensive People with Type l Diabetes”,The Lancet, vol. 351, Jan. 3, 1998.
Cohen, et al., “The Effect of Copper Chelating Drugs on Liver Iron Mobilization on the Adult Rat”,Biochemical and Biophysical R Communication, vol. 113, No. 1, May 31, 1983, 127-135.
Dahlman et al., Long-Term Treatment of Wilson's Disease with Triethylene Tetramine Dihydrochloride (Trientine),O/Med, 1995: 88:609-616.
Deckert, et al., “Prognosis of Diabetics with Diabetes Onset before the Age of Thirtyone”,Diabetologia, 14, 363-370 (1978).
Dwivedi, et al., The Effect of Triethylene Tetramine upon the Selective Removal of Nickel (II), Iron (II), Manganese (II) and tin (II) in Rats,Chemosphere, No. 11, pp. 925-932, 1978; Pergamon Press, Great Britain.
Duffy et al., “Iron Chelation Improves Endothelial Function in Patients with Coronary Artery Disease”,Circulation. 2001; 103:2799-28204.
Epstein et al., “Triethylene Tetramine Dihydrochloride Toxicity in Primary Biliary Cirrhosis”,Gastroenterology, 78:1442-1445, 1980.
Green, et al., Stoichiometry of O2Metabolism and NADPH Oxidation of the Cell-free Latent Oxidase Reconstituted from Crytosol and Solubilized Membrane from Resting Human NeutrophilsThe Journal of Biological Chemistry, vol. 268, No. 2, Jan. 15, pp. 857-861, 1993.
Greenman et al., “Subchronic Toxicity of Trethylenetetramine Dihydrochloride in B6C3F1 Mice and F344 Rats”,Fundamental and Applied Toxicology, 29, 185-193 (1996) Article No. 0020.
Haslam et al, “Treatment of Wilson's Disease with Triethylene Tetramine Dihydrochloride”,Dev. Pharmacol. Ther. I, 1:318-324 (1980).
Howes et al., “Role of Stored Iron in Atherosclerosis”,Journal of Vascular Nursing, vol. XVIII, No. 4, 109-114, no date available.
Hunt et al., “Ascorbic Acid Oxidation: a Potential Cause of the Elevated Severity of Atherosclerosis in Dibetes Mellitus?”, FEBS 11659, vol. 311, No. 2, 161-164, no date available.
Ido, et al., “Interactions between the Sorbitol Pathway, Non-Enzymatic Glycation, and Diabetic Vascular Dysfunction”,Nephrol Dial Transplant, (1996) 11 [Suppl 5]: 72-75.
Iseki et al., “Comparison of Disposition Behavior and De-Coppering Effect of Triethylenetetramine in Animal Model for Wilsoon's Disease (Long-Evans Cinnamon Rat) with Normal Wistar Rat”,Biopharmaceutics & Drug Disposition, vol. 13, 273-283 (1992).
Keegan, et al., “Transition Metal Chelators and Anti-Oxidants Prevent the Development of Defective Endothelium-depend Relaxation in Aortas from Diabetic Rats”, (Abstract), No date available.
Keegan et al., “Effects of Chelator Treatment on Aorta and Corpus Cavemosom from Diabetic Rats”,Free Radical Biology & Medicine, vol. 27, Nos. 5/6, pp. 536-543, 1999.
Kodama et al., “Metabolism of Administered Tetramine Diydrochloride in Humans”,Life Sciences, vol. 61, No. 9, pp. 899-907, 1997.
Laight et al., “Microassay of Superoxide Anion Scavenging Activity in Vitro”,Environmental Toxicology and Pharmacology, 3 (1997) 65-68.
Love et al., “Nerve Function and Regeneration in Diabetic and Galactosaemic Rats: Antioxidant and Metal Chelator Effects”,European Journal of Pharmacology, 314 (1996) 33-39.
McCord et al., An Enzymic Function for Erythrocuprein (Hemocuprein),The Journal of biological Chemistry, vol. 244, No. 22, Nov. 25, pp. 6049-6055 (1969).
McQuaid et al., “A Comparison of the Effects of Penicillamine, Trientine, and Trithiomolybdate on [35S]-Labeled Metallot Vitro; Implications for Wilson's Disease Therapy”,Journal of Inorganic Biochemistry, 41, 87-92 (199
Baker John R.
Cooper Garth J. S.
Buchanan Ingersoll P.C.
Henley III Raymond J.
Protemix Corporation Limited
LandOfFree
Preventing and/or treating cardiovascular disease and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing and/or treating cardiovascular disease and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing and/or treating cardiovascular disease and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3444752